Ausgabe 4/2013
Inhalt (13 Artikel)
The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer
Judy S. Wang, Michael B. Foote, Khalid A. Jazieh, Luis A. Diaz Jr
Oncotype DX for Colon Cancer: Are We Ready for Prime Time in Personalized Medicine?
James J. Lee, Edward Chu
Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?
Maria Ignez Braghiroli, Rachel P. Riechelmann, Jorge Sabbaga, Paulo M. Hoff
How Do We Make Choices in Salvage Therapy: Panitumumab, Cetuximab, or Regorafenib?
Elena Tsvetkova, Timothy R. Asmis
Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention
Lin Zhang, Jian Yu
Stem Cell Signaling Pathways in Colorectal Cancer
B. S. Ramakrishna, Sam Vijay Kumar
Reactive Oxygen Species and Colorectal Cancer
Sandeep Sreevalsan, Stephen Safe
Honokiol as a Radiosensitizing Agent for Colorectal Cancers
Zhiyun He, Dharmalingam Subramaniam, Zhongtao Zhang, Youcheng Zhang, Shrikant Anant
Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation
Murali D. Bashyam, Ratheesh Raman
The Association of Immune Cell Infiltration and Prognosis in Colorectal Cancer
Richard Palmqvist, Maria L. Wikberg, Agnes Ling, Sofia Edin
Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer
Vanessa Deschoolmeester, Evelien Smits, Marc Peeters, Jan B. Vermorken
Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer
Sandip P. Patel, Takuya Osada, Koya Osada, Herbert Hurwitz, H. Kim Lyerly, Michael A. Morse
Viral Vector Vaccines To Treat Colorectal Cancer
N. Ashraf, A. Mahipal, R. Kim